|
Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors. |
|
|
Research Funding - Merrimack; Merrimack (Inst); Novartis; Novartis (Inst) |
|
|
Research Funding - Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Consulting or Advisory Role - Lilly |
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
Travel, Accommodations, Expenses - Novartis; Roche Pharma AG |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Honoraria - Lilly; Roche Pharma AG |
Consulting or Advisory Role - Lilly; Roche Pharma AG |
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
Research Funding - Merrimack; Merrimack (Inst) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|